Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables - Other: 2017-2024

Historic Receivables - Other for Autolus Therapeutics (AUTL) over the last 8 years, with Dec 2024 value amounting to $1.4 million.

  • Autolus Therapeutics' Receivables - Other rose 56.52% to $936,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $936,000, marking a year-over-year increase of 56.52%. This contributed to the annual value of $1.4 million for FY2024, which is 175.39% up from last year.
  • As of FY2024, Autolus Therapeutics' Receivables - Other stood at $1.4 million, which was up 175.39% from $516,000 recorded in FY2023.
  • Over the past 5 years, Autolus Therapeutics' Receivables - Other peaked at $1.4 million during FY2022, and registered a low of $384,000 during FY2021.
  • Over the past 3 years, Autolus Therapeutics' median Receivables - Other value was $1.4 million (recorded in 2024), while the average stood at $1.1 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Receivables - Other crashed by 68.96% in 2021, and later surged by 273.70% in 2022.
  • Autolus Therapeutics' Receivables - Other (Yearly) stood at $1.2 million in 2020, then plummeted by 68.96% to $384,000 in 2021, then spiked by 273.70% to $1.4 million in 2022, then slumped by 64.04% to $516,000 in 2023, then surged by 175.39% to $1.4 million in 2024.